FDA’s advisory committee on testosterone-replacement products highlighted a regulatory conundrum the agency faces in terms of oversight of disease-awareness ads, and also illuminated potential promotional opportunities for marketers outside of the testosterone class.
The Sept. 17 advisory panel meeting may result in what could be seen as an overly convoluted regulatory procedure – changing product labeling to address what many see essentially as a marketing problem
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Pink Sheet for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?